Freedom of Information request 016200

24/5/22

Please see table below with current open studies. Some are still recruiting patients, others have finished recruiting but patients are still on follow-up :

Project Short title	Project Full title	IRAS Number	NIHR Portfolio Study ID	Project type	DGH disease area	Project site status	Project site Start date (NHS Permission)	Project site date open to recruitment	Project site planned recruitment end date	Project site target participants	patients Recruited (total)
AML18	A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome			Non-commercial portfolio	Cancer	Open	15/12/2014	15/12/2014	31/07/2022	16	17
AML19	Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome			Non-commercial portfolio	Cancer	Suspended	04/01/2016	04/01/2016	11/12/2019	11	13
CALLS - CML and ALL Low Level Mutation Study	A Cohort Study To Establish the Prevalence of Mutations in Patients with CML Who Meet the ELN Criteria for Warning or Failure and Patients With Ph+ALL With Detectable BCR-ABL1 Currently Being Treated With First or			Commercial portfolio	Cancer	Closed to recruitment - in follow up		18/05/2018	31/12/2020	6	5

	Subsequent TKI Therapy in the UK Using Next Generation Sequencing										
FLAIR	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab			Non-commercial portfolio	Cancer	Open		04/08/2014	21/08/2014	31/01/2023	10	23
Investigating DNA damage repair defects in Haematological malignancies	Investigating DNA repair defects in Chronic Lymphocytic Leukaemia, multiple myeloma and other related lymphoid tumours with a view to novel therapies			Non-commercial portfolio	Cancer	Open			30/05/2017	01/07/2025	10	3
The UK National Registry of Chronic Myeloid Leukaemia	The UK National Registry of Chronic Myeloid Leukaemia			Non-commercial non-portfolio	Cancer	Open			23/09/2016		5	4
Zanubrutinib + Rituximab vs Bendamustine + Rituximab for untreated MCL	A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma			Commercial portfolio	Cancer	Open			21/06/2021	31/07/2022	2	0

	Who Are Ineligible for Stem Cell Transplantation										